MASATAKA TSUGE

Last Updated :2020/07/01

Affiliations, Positions
Natural Science Center for Basic Research and Development, Assistant Professor
E-mail
tsugehiroshima-u.ac.jp

Basic Information

Major Professional Backgrounds

  • 2006/04/01, 2007/01/31, Viral Hepatitis Research Fundation of Japan, Research resident A
  • 2007/02/01, 2007/03/31, Hiroshima university hospital, Department of Gastroenterology, Assistant professor of Hiroshima university
  • 2007/04/01, 2008/03/31, Hiroshima university hospital, Department of Gastroenterology, Assistant professor of Hiroshima university
  • 2008/04/01, Natural Science Center for Basic Research and Development, Assistant professor of Hiroshima university

Educational Backgrounds

  • Hiroshima University, Japan, 2002/04, 2006/03
  • Hiroshima University, Faculty of Medicine, Japan, 1992/04, 1998/03

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Gastroenterology

Research Keywords

  • Viral hepatitis

Affiliated Academic Societies

  • The Japanese Society for Virology, 2003
  • The Japanese Society of Internal Medicine, 1998
  • Japan Gastroenterological Endoscopy Society, 2000
  • The Japanese Society of Gastroenterology, 2000
  • Japanese Cancer Association, 2005
  • The Japan Society of Hepatology, 2002
  • Japanese Society of Molocular Medicine, 2005

Educational Activity

Course in Charge

  1. 2020, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2020, Undergraduate Education, Intensive, Symptomatology, Diagnosis and Treatment
  3. 2020, Undergraduate Education, Intensive, Practice for medical research

Research Activities

Academic Papers

  1. Detection of hepatitis B core antibody (including IgM and IgA class antibodies), 62(増刊号8), 129-133, AUG 2004
  2. G to A hypermutation of hepatitis B virus, HEPATOLOGY, 41(3), 626-633, MAR 2005
  3. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5 ' flanking region of SMYD3 is a risk factor for human cancers, NATURE GENETICS, 37(10), 1104-1107, OCT 2005
  4. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus, HEPATOLOGY, 42(5), 1046-1054, NOV 2005
  5. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 50(11), 3867-3874, NOV 2006
  6. Enhanced SMYD3 expression is essential for the prowth of breast cancer cells., Cancer Sci, 97(2), 113-118, FEB 2006
  7. Dual effect of APOBEC3G on Hepatitis B virus, JOURNAL OF GENERAL VIROLOGY, 88, 432-440, FEB 2007
  8. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine, HEPATOLOGY, 45(5), 1179-1186, MAY 2007
  9. Successful treatment of an entecavir-resistant hepatitis B virus variant, JOURNAL OF MEDICAL VIROLOGY, 79(12), 1811-1817, DEC 2007
  10. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells., Oncogene, NOV 2007
  11. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 89, 2108-2113, SEP 2008
  12. A Case of Fulminant Hepatic Failure Caused by Hepatitis E virus79117, Clinical Journal of gastroenterology, 1, 69-74, JUN 2008
  13. The first Japanese case of COACH syndrome, HEPATOLOGY RESEARCH, 39(3), 318-323, MAR 2009
  14. A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C, GASTROENTEROLOGY, 136(5), 1796-1805, MAY 2009
  15. Ecabet sodium induces neuronal nitric oxide synthase-derived nitric oxide synthesis and gastric adaptive relaxation in the human stomach, JOURNAL OF GASTROENTEROLOGY, 44(11), 1118-1124, NOV 2009
  16. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice, JOURNAL OF HEPATOLOGY, 51(6), 1046-1054, DEC 2009
  17. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection, HEPATOLOGY RESEARCH, 39(12), 1159-1168, DEC 2009
  18. G-to-A Hypermutation in Hepatitis B Virus (HBV) and Clinical Course of Patients with Chronic HBV Infection, JOURNAL OF INFECTIOUS DISEASES, 199(11), 1599-1607, JUN 2009
  19. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy, ANTIVIRAL THERAPY, 15(8), 1087-1097, DEC 2010
  20. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B, ANTIVIRAL THERAPY, 15(2), 177-184, APR 2010
  21. G to A hypermutation of TT virus, VIRUS RESEARCH, 149(2), 211-216, MAY 2010
  22. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 91, 1854-1864, JUL 2010
  23. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor, JOURNAL OF GENERAL VIROLOGY, 91, 1668-1677, JUL 2010
  24. Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8), 3205-3211, AUG 2010
  25. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients, JOURNAL OF HEPATOLOGY, 53(3), 439-443, SEP 2010
  26. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus, SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 45(12), 1488-1496, DEC 2010
  27. Animal model for study of human hepatitis viruses, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 26(1), 13-18, JAN 2011
  28. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b, JOURNAL OF HEPATOLOGY, 54(3), 408-414, MAR 2011
  29. Impact of Radiation and Hepatitis Virus Infection on Risk of Hepatocellular Carcinoma, HEPATOLOGY, 53(4), 1237-1245, APR 2011
  30. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice, JOURNAL OF HEPATOLOGY, 54(5), 872-878, MAY 2011
  31. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy, JOURNAL OF MEDICAL VIROLOGY, 83(6), 1048-1057, JUN 2011
  32. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy, JOURNAL OF HEPATOLOGY, 54(6), 1094-1101, JUN 2011
  33. Prediction of Response to Peginterferon-Alfa-2b Plus Ribavirin Therapy in Japanese Patients Infected With Hepatitis C Virus Genotype 1b, JOURNAL OF MEDICAL VIROLOGY, 83(6), 981-988, JUN 2011
  34. Impact of Viral Amino Acid Substitutions and Host Interleukin-28B Polymorphism on Replication and Susceptibility to Interferon of Hepatitis C Virus, HEPATOLOGY, 54(3), 764-771, SEP 2011
  35. Inverse Association of IL28B Genotype and Liver mRNA Expression of Genes Promoting or Suppressing Antiviral State, JOURNAL OF MEDICAL VIROLOGY, 83(9), 1597-1607, SEP 2011
  36. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain from Wildtype Clone In Vivo, HEPATOLOGY, 54(3), 781-788, SEP 2011
  37. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma, JOURNAL OF VIRAL HEPATITIS, 18(10), E550-E560, OCT 2011
  38. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region, HEPATOLOGY RESEARCH, 41(11), 1126-1131, NOV 2011
  39. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo, JOURNAL OF HEPATOLOGY, 55(1), 11-18, JUL 2011
  40. A first case of hepatic angiosarcoma treated with recombinant interleukin-2, Hiroshima J. Med. Sci., 60(4), 91-6, DEC 2011
  41. Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse, PLOS ONE, 6(8), AUG 2011
  42. Effects of Hepatitis B Virus Infection on the Interferon Response in Immunodeficient Human Hepatocyte Chimeric Mice, JOURNAL OF INFECTIOUS DISEASES, 204(2), 224-228, JUL 2011
  43. Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon alpha-2b to alpha-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report, INTERVIROLOGY, 55(4), 306-310, APR 2012
  44. Identification of novel HCV deletion mutants in chronic hepatitis C patients, ANTIVIRAL THERAPY, 17(8), 1551-1561, AUG 2012
  45. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B, HEPATOLOGY RESEARCH, 42(2), 139-149, FEB 2012
  46. Serum PAI-1 is a novel predictor for response to pegylated interferon-a-2b plus ribavirin therapy in chronic hepatitis C virus infection, JOURNAL OF VIRAL HEPATITIS, 19(2), E126-E133, FEB 2012
  47. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients, JOURNAL OF GASTROENTEROLOGY, 47(7), 834-844, JUL 2012
  48. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse, HEPATOLOGY, 56(2), 555-566, AUG 2012
  49. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 27(9), 1467-1472, SEP 2012
  50. Migration to the pulmonary artery of nine metallic coils placed in the internal iliac vein for treatment of giant rectal varices.Wataru Yamasaki, Hideaki Kakizawa, Masaki Ishikawa, Shuji Date, ;Fuminari Tatsugami, Hiroaki Terada, Keiichi Masaki, Tomokazu Kawaoka, Masataka Tsuge, Hiroshi Aikata, Kazuaki Chayama, and Kazuo Awai.Acta Radiol.1(6),2012, Acta Radiol, 1(6), JUL 2012
  51. Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle, PLOS ONE, 7(10), OCT 2012
  52. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B, JOURNAL OF MEDICAL VIROLOGY, 85(5), 789-798, MAY 2013
  53. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice, GUT, 62(7), 1055-1061, JUL 2013
  54. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 48(7), 847-855, JUL 2013
  55. A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing, AMERICAN JOURNAL OF GASTROENTEROLOGY, 108(9), 1464-1472, SEP 2013
  56. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients, JOURNAL OF GASTROENTEROLOGY, 48(10), 1188-1204, OCT 2013
  57. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases, HEPATOLOGY RESEARCH, 43(11), 1182-1189, NOV 2013
  58. Availability of monitoring serum HBV DNA plus RNA during nucleot(s)ide analogue therapy., J Gastroenterology, 48(6), 779-780, JUN 2013
  59. HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study, PLOS ONE, 8(12), E84226, DEC 2013
  60. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 441(1), 230-235, NOV 2013
  61. Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients, HEPATOLOGY RESEARCH, 44(3), 280-287, MAR 2014
  62. Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(4), 2105-2112, APR 2014
  63. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29(5), 1035-1042, MAY 2014
  64. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients, HEPATOLOGY RESEARCH, 44(7), 740-749, JUL 2014
  65. Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation, HEPATOLOGY RESEARCH, 45(11), 1047-1054, NOV 2015
  66. A case of syndrome of inappropriate secretion of antidiuretic hormone following transarterial embolization with cisplatin, 111(9), 1805-1810, SEP 2014
  67. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA, JOURNAL OF VIRAL HEPATITIS, 21(9), E89-E97, 201409
  68. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation, HEPATOLOGY RESEARCH, 44(12), 1259-1264, NOV 2014
  69. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C, HEPATOLOGY RESEARCH, 44(14), E447-E454, DEC 2014
  70. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease, HEPATOLOGY RESEARCH, 44(14), E420-E427, DEC 2014
  71. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49(12), 1548-1556, DEC 2014
  72. Serum interleukin-6 associated with hepatocellular carcinoma risk: A nested case-control study, INTERNATIONAL JOURNAL OF CANCER, 134(1), 154-163, JAN 2014
  73. Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus, HEPATO-GASTROENTEROLOGY, 61(130), 323-328, MAR-APR 2014
  74. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy, ANTIVIRAL THERAPY, 20(4), 369-375, 201504
  75. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1, JOURNAL OF VIRAL HEPATITIS, 22(2), 158-165, FEB 2015
  76. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism, JOURNAL OF VIRAL HEPATITIS, 22(2), 166-174, FEB 2015
  77. Differences in serum microRNA profiles in hepatitis B and C virus infection, JOURNAL OF INFECTION, 70(3), 273-287, MAR 2015
  78. A second attack of cholestasis associated with erythropoietic protoporphyria was successfully treated by plasma exchange and blood transfusion, Clinical journal of gastroenterology, 7(4), 333-337, AUG 2015
  79. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30(4), 726-732, APR 2015
  80. Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report, TRANSPLANTATION PROCEEDINGS, 47(3), 809-814, APR 2015
  81. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 45(6), 656-662, JUN 2015
  82. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 45(6), 607-617, JUN 2015
  83. Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases, EUROPEAN JOURNAL OF RADIOLOGY, 84(8), 1540-1545, AUG 2015
  84. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A, JOURNAL OF HEPATOLOGY, 63(3), 554-563, SEP 2015
  85. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30(3), 619-627, MAR 2015
  86. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice, ANTIVIRAL THERAPY, 21(4), 307-315, APR 2016
  87. Factors associated with the effect of interferon-alpha sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B, Hepatology research, 45(12), 1195-1202, DECEMBER 2015
  88. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients, Hepatology Research, 46(8), 758-764, JULY 2016
  89. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones, JOURNAL OF INFECTION, 72(1), 91-102, 201601
  90. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31(5), 1009-1015, MAY 2016
  91. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir andBMS-788329 combination therapy in human hepatocyte chimeric mice, VIRUS RESEARCH, 213, 62-68, FEB 2016
  92. Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice, JOURNAL OF VIROLOGY, 89(19), 10087-10096, OCT 2015
  93. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy, JOURNAL OF MEDICAL VIROLOGY, 87(11), 1913-1920, NOV 2015
  94. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma, EUROPEAN RADIOLOGY, 25(11), 3272-3281, NOV 2015
  95. Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus, HEPATOLOGY RESEARCH, 46(3), E146-E153, MAR 2016
  96. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46(9), 944-948, AUG 2016
  97. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report, HEPATOLOGY RESEARCH, 46(7), 707-712, JUN 2016
  98. Preoperative Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Prediction of Microvascular Invasion in Small Hepatocellular Carcinoma., Journal of Computer Assisted Tomography, 40(4), 524-530, JUL-AUG 2016
  99. ITPA polymorphism effects on decrease of hemoglobin during simeprevir, pegylated interferon and ribavirin combination treatment for chronic hepatitis C., Hepatology Research
  100. IFNL4 polymorphism effects on outcome of simeprevir, peginterferon and ribavirin therapy for older patients with genotype 1 chronic hepatitis C., Hepatology Research, 47(3), E5-E13, MAR 2017
  101. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection, JOURNAL OF GASTROENTEROLOGY, 51(11), 1073-1080, 201611
  102. The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study, JOURNAL OF GASTROENTEROLOGY, 52(1), 113-122, JAN 2017
  103. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing, JOURNAL OF INFECTIOUS DISEASES, 214(11), 1687-1694, DEC 1 2016
  104. Efficacy and Safety of Daclatasvir Plus Asunaprevir Therapy for Chronic Hepatitis C Patients With Renal Dysfunction, JOURNAL OF MEDICAL VIROLOGY, 89(4), 665-671, APR 2017
  105. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus, PLOS ONE, 12(3), MAR 2 2017
  106. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 52(2), 253-262, FEB 2017
  107. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52(3), 366-375, MAR 2017
  108. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 32(3), 645-650, MAR 2017
  109. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52(4), 504-511, APR 2017
  110. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52(6), 746-753, JUN 2017
  111. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib, ONCOLOGY, 92(6), 335-346, 2017
  112. ARFI : a new non-invasive method for evaluation of liver fibrosis, Kanzo, 50(8), 467-469, 20090825
  113. The efficacy of sequential treatment with lamivudine and alpha-interferon in anti-HBe-negative chronic hepatitis B patients -Examination of HBsAg seroclearance-, Kanzo, 54(10), 720-722, 2013
  114. Universal hepatitis B vaccination : pros and cons, Kanzo, 50(10), 598-604, 20091025
  115. Universal vaccination of hepatitis B virus vaccine, Kanzo, 53(2), 117-130, 20120225
  116. A case of acute hepatitis C with hepatitis C virus (HCV) genotype 3a : discussion of IL28-B, Kanzo, 54(2), 120-127, 20130225
  117. A case of clonorchiasis complicated with the expansion of liver cyst, Nippon Shokakibyo Gakkai Zasshi, 110(3), 456-464, 20130305
  118. A case of intrahepatic splenosis after splenic rupture with difficulty in preoperative diagnosis, Kanzo, 54(5), 317-325, 20130525
  119. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice, Journal of Hepatology, 51(6), 1046-1054, 200912
  120. A First Case of Hepatic Angiosarcoma Treated with Recombinant Interleukin-2, Hiroshima Journal of Medical Sciences, 60(4), 91-96, 201112
  121. A case of syndrome of inappropriate secretion of antidiuretic hormone following transarterial embolization with cisplatin, Nippon Shokakibyo Gakkai Zasshi, 111(9), 1805-1810, 2014
  122. Hepatitis B infection derived from a donor and de novo autoimmune hepatitis subsequent to pegylated-interferon treatment for recurrent hepatitis C after living-liver transplantation: A case report, Kanzo, 55(10), 604-611, 2014
  123. Analysis of the anti-viral effects with nucleot(s)ide analogues using human hepatocyte chimeric mouse, 229(1), 11-16, 20090404
  124. The analysis of the chronic hepatitis B patients who discontinued the treatments with nucleotide analogues, Gastroenterology, 53(3), 300-308, 201109
  125. Anti-viral effects of tenofovir for HBV mutants, 54(5), 575-581, 201205
  126. Effects of HBV infection on the interferon response in immunodeficient human hepatocyte chimeric mice, 58(2), 231-238, 201402
  127. Persistent Loss of HBV Markers in Serum without Cellular Immunity by Combination of PEG-IFN Plus ETV Therapy in Humanized Mice., Antimicrob Agents Chemother
  128. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients., J Med Virol
  129. A case of chronic inflammatory demyelinating polyradiculoneuropathy after treatment with pegylated interferon alpha-2a in a patient with chronic hepatitis B virus infection, Rinsho Shinkeigaku, 56(10), 672-677, OCT 2016
  130. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C, Hepatol Res, 46(12), 1256-1263, NOV 2016
  131. Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection, Hepatol Res, 47(8), 767-772, JUL 2017
  132. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, J Gastroenterol, 52(3), 366-375, MAR 2017
  133. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy, J Gastroenterol
  134. Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia, Clin J Gastroenterol
  135. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, J Gastroenterol
  136. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma, Hepatol Res
  137. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury, J Gastroenterol
  138. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, J Gastroenterol
  139. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus, Antimicrob Agents Chemother, 61(6), 201706
  140. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, Hepatol Res
  141. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation, Clin J Gastroenterol, 10(2), 179-184, APR 2017
  142. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology, J Gen Virol, 98(5), 1040-1047, MAY 2017
  143. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology, JOURNAL OF GENERAL VIROLOGY, 98(5), 1040-1047, MAY 2017
  144. Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection, HEPATOLOGY RESEARCH, 47(8), 767-772, JUL 2017
  145. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12(8), AUG 10 2017
  146. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients, JOURNAL OF MEDICAL VIROLOGY, 89(11), 1963-1972, NOV 2017
  147. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation, CLINICAL JOURNAL OF GASTROENTEROLOGY, 10(2), 179-184, APR 2017
  148. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury, JOURNAL OF GASTROENTEROLOGY, 52(12), 1252-1257, DEC 2017
  149. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53(1), 107-118, JAN 2018
  150. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 48(1), 51-58, JAN 2018
  151. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48(2), 193-204, FEB 2018
  152. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53(2), 269-280, FEB 2018
  153. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, HEPATOLOGY RESEARCH, 48(4), 264-274, MAR 2018
  154. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study, JOURNAL OF GASTROENTEROLOGY, 53(4), 548-556, APR 2018
  155. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis, ONCOLOGY, 94(4), 215-222, 2018
  156. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring, PLOS ONE, 13(4), APR 3 2018
  157. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(9), SEP 2017
  158. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 500(2), 152-157, JUN 2 2018
  159. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial, BMC CANCER, 18, JUN 4 2018
  160. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, JOURNAL OF GENERAL VIROLOGY, 99(8), 1058-1065, AUG 2018
  161. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice, HEPATOLOGY RESEARCH, 48(10), 814-820, SEP 2018
  162. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 33(10), 1780-1786, OCT 2018

Awards

  1. 2016/02/24, Young Investigator Award, The Asian Pacific Association for the Study of the Liver (APASL), Nucleotide analogues improve interferon responsiveness in HBV-infected human hepatocytes

Works, etc.

  1. B型肝炎ウイルス感染に伴う肝発癌候補遺伝子の網羅的解析とそのメカニズムの解明, 2007/06
  2. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus., 2007/02
  3. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus., 2006/10